To identify small-molecule modulators of biologic systems, academic scientists are beginning to use high-throughput screening (HTS) approaches that have traditionally been used only in industry. The HTS laboratories that are being established in universities, while differing in details of staffing, equipment, and size, have all been created to attain 1 or more of 3 principal goals: drug discovery, chemical genetics, or training. This article will examine the role that these activities play in 4 HTS laboratories that have been created within the academic community of Harvard Medical School and its affiliated institutions. First, the 3 activities will be defined with special attention paid to describing the impact they are having on how academic biologic science is conducted today. Next, the histories and operations of the 4 Harvard laboratories are reviewed. In the course of these summaries, emphasis is placed on understanding the motivational role that the 3 activities initially played in the creation of the 4 Harvard facilities and the roles that the activities continue to play in their day-to-day operations. Finally, several concerns are identified that must be attended to for the successful establishment and operation of an academic biologic science that has yet to be fully determined. HTS has the ability to provide the tools to test previously untestable hypotheses and can thereby allow the discovery of the unanticipated and the truly novel. (Journal of Biomolecular Screening 2003:615-619) 
I
N RECENT YEARS, academic research in the biological sciences has undergone a dramatic shift in methodological emphasis in how it goes about answering its questions. Although hypothesisdriven modes of inquiry still remain the ideal, stochastic approaches are playing an ever-increasing role in our "postgenomic" age. Among these approaches are those that seek to identify molecules that possess the ability to modulate specific biological processes. To discover such molecules, academic scientists are supplementing design-based methods with high-throughput screening (HTS) approaches that have traditionally been the purview of industry. We are now seeing academic institutions establish laboratories that are devoted entirely to HTS, and although these laboratories differ widely in details of staffing, equipment, and size, they have all been created to attain 1 or more of 3 principal goals: drug discovery, chemical genetics, or training.
In this article, I will explore the role that these activities play in 4 HTS laboratories that have been created within the academic community of Harvard Medical School and its affiliated teaching hospitals and institutions. We will first have a look at how these activities are defined and try to understand the role they are playing in determining how academic biologic science is conducted today. Next, we will review the histories and operations of the 4 laboratories. In the course of these summaries, we will be able to see the motivational role that the 3 activities initially played in their creation and the roles that they continue to play in their day-to-day operations. Finally, I will comment on several concerns that must be attended to for the successful establishment and operation of an academic HTS lab.
ACTIVITIES THAT MOTIVATE ACADEMIC HTS

Drug discovery
For the past 15 years or more, the pharmaceutical industry has been engaged in a fascinating experiment. In this experiment, pharma is testing the hypothesis that screening thousands of structurally diverse compounds for their ability to modulate diseaserelevant biological systems will yield molecules that can be optimized into drugs. Anecdotal accounts of these endeavors, as well as some quantitative analyses, allow guarded optimism for the out-come of this still ongoing experiment. 1 Thus, HTS currently stands alongside design-and natural product-based methods for the identification of foundational structures from which to launch focused programs of medicinal chemical optimization.
Recently, a number of academic labs have adopted HTS technologies and are using them in their own drug discovery efforts. To some onlookers, this is a puzzling turn of events. Given the success that pharma has enjoyed in bringing new drugs to market, the obvious question is why such efforts are being pursued in academics. Although a number of reasons are likely at play here, I believe the principal reason is to counter the risk aversion that exists as a general characteristic of big pharma drug discovery programs. 2 It is well appreciated that by its very nature, drug discovery is risky business. These risks exist for a drug discovery organization in 2 principal arenas: in the market place, where risk increases with rarity of the disease that is being targeted, and in the laboratory, where discovery risk increases in proportion to the difficulty and the uniqueness of the molecular target or discovery approach. The academic scientists that have established these new HTS labs for the purpose of drug discovery recognize that only with the involvement of academia can the entire risk landscape be covered. They understand that the mandate of National Institutes of Healthfunded academic labs must be to provide the taxpayer some measure of return on their tax dollars in the form of drug discovery research in disease areas that are neglected by big and small drug pharmaceutical companies.
Chemical genetics
Chemical genetics refers to a family of related methodologies in which small organic molecules are used to systematically perturb and probe intracellular processes with the goal of identifying the proteins, enzymes, and receptors that participate in those processes. 3 These are powerful methodologies, offering the ability to finely dissect complex biological processes. For example, in one application of chemical genetics that takes advantage of HTS technologies, thousands of compounds are tested for their ability to induce a desired or inhibit an undesired cellular phenotype. Positives from such an assay would then be used to identify the proteins and pathways that give rise to the phenotype.
Although chemical genetics is typically thought to be pursued only in academic laboratories, less systematic predecessors of this approach have been part of pharmaceutical drug discovery efforts for years. It is not uncommon for cell-based screens that are conducted in pharma to generate potent hits that interact with unknown intracellular targets. These hits are used as starting points and molecular tools for programs of research to identify a "drugable" disease target. A now-classic example of this can be found in the discovery of FLAP (5-lipoxygenase activating protein) at the Merck Frosst labs in the late 1980s. 4, 5 The identification of this critical protein in leukotriene biosynthesis was made possible from studies of how a novel class of indoles indirectly inhibits 5-lipoxygenase in whole cells.
Training
Until recently, there have been few university programs for training students in the methodologies of drug discovery research. This has now begun to change with programs such as the Drug Discovery Program at Northwestern University (http://ddp.northwestern.edu/), which offers multidisciplinary undergraduate, predoctoral, and postdoctoral programs in the methodologies of drug discovery, including elucidation of disease-relevant intracellular regulatory pathways, drug discovery target identification and characterization, and optimization strategies for first-generation chemical compounds for biological and pharmacological research. The training that these students receive as part of degree and postdegree programs should be a valuable asset to both the student, as she or he competes with peers for jobs in pharma and biotech, and to companies, who will now be able to hire individuals who not only have training in traditional biological disciplines but also in jobrelevant, highly specialized areas.
SCREENING LABORATORIES OF THE HARVARD MEDICAL SCHOOL SYSTEM
Institute for Chemistry and Cell Biology (ICCB)
The ICCB (http://iccb.med.harvard.edu) was founded in 1997 with the goal of promoting chemical genetics as an academic field. The principal goals of the ICCB are to develop synthetic strategies to make large libraries of small molecules with natural productlike characteristics and then to use HTS technologies to identify novel tool compounds among the molecules of these libraries with which to understand complex biological processes.
The ICCB established one of the first academic labs for HTS and uses what they call an Investigator-Initiated Screening Program, funded largely by the National Cancer Institute's Initiative for Chemical Genetics to provide access for research groups nationwide to the ICCB HTS facility. A key feature of this program is that researchers are under no constraint to screen against only those targets or pathways that are likely to lead to drugs but rather are free to explore any pathway of biological interest. Other features that make working with the ICCB very attractive are that 1) no fee is charged for screening, 2) a staff member is available to provide advice on all aspects of HTS, and 3) a large library of 250,000 compounds exists for screening. Screening at the ICCB has been enormously productive and has evolved into a highly versatile, userfriendly system in which a great variety of assay methods are used to explore diverse pathways from many organisms (a bibliography of ICCB's publications can be found at http://iccb.med.harvard. edu/publications.htm).
A critical part of screening at ICCB is the unique way that data are handled. Ever cognizant of patenting concerns that may surface in the future, ICCB has established a system in which data that are generated during screening are available to all ICCB investigators but are also held as confidential in such a way so that their deposition does not constitute public disclosure. In this way, data can be compared across screens by interested ICCB investigators but are also protected.
Laboratory for Drug Discovery in Neurodegeneration (LDDN)
Neurodegenerative disease (ND) is a family of central nervous system disorders that are characterized by progressive cell death of disease-specific neurons that ultimately leads to severe cognitive and motor deficits. These diseases currently affect more than 5 million people in the United States alone, and by 2010, 20 million people worldwide are projected to suffer from some form of ND. 6 Despite the large numbers suffering from ND and the even greater number anticipated in our "graying" population, ND remains a critical unmet medical need. Although the annual research and development budget of the pharmaceutical industry increased from $15 billion to $30 billion and resulted in 240 new drugs, less than 10 of these are for ND and not one treats degenerative processes. 6 It is clear that the discovery of disease-modifying drugs for ND will require the implementation of a new research model that is not so dependent on pharma. One such model has been put into operation in the LDDN. 2 The LDDN was established in 2001 as a core group within the then newly created Harvard Center for Neurodegeneration and Repair (http://hcnr.med.harvard.edu). The mission of the LDDN is to discover chemical agents that can be used as lead structures for the development of new therapeutics. To discover these compounds, LDDN screens large collections of drug-like molecules for their ability to modulate the biological activity of molecular and cellular processes that are thought to play causative roles in NDs. Optimization of these compounds to enhance therapeutically relevant properties is achieved by focused programs of medicinal chemistry.
Several novel elements of the design of the LDDN should be emphasized:
• The LDDN is staffed and managed by professionals with extensive experience in the biopharmaceutical industry. In addition to ensuring technical expertise in relevant areas including assay development, automation, informatics, and medicinal chemistry, this feature also creates a product-oriented culture that does not exist in most academic centers.
• Each drug discovery program starts as a collaboration between the permanent staff of the LDDN and an investigator from the collaborating laboratory. The scientist from the collaborating laboratory spends between 8 and 15 mos working with the permanent staff of the LDDN. This not only ensures that adequate background knowledge from the collaborating laboratory exists on site but also serves an invaluable training function for the collaborating laboratory into the distinctive methodologies and philosophies of assay development, HTS, and medicinal chemistry.
• The screening LDDN undertakes is both mechanism based and hypothesis driven. Target selection is based on current understanding of underlying pathogenic mechanisms. Compounds, once identified, are then used to test hypotheses about disease mechanism.
This becomes an iterative cycle in which compounds that are discovered based on mechanistic knowledge are then used to test hypotheses, refine mechanistic proposals, and, finally, stimulate selection of new targets.
• LDDN not only screens a large collection of drug-like molecules but also a library of 650 FDA-approved drugs. The driving force behind this latter activity is to accelerate entry of safe and wellunderstood drugs into clinical trials.
The LDDN is currently working on projects in 5 disease areas: Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis. At any one time, LDDN is working on more than 15 projects. Since it became fully operational in January of 2002, LDDN has successfully screened nearly a dozen targets, and about as many are currently being screened. Despite the relative youth of the LDDN, a number of projects have yielded publishable studies [7] [8] [9] as well as starting points for medicinal chemistry projects and molecules that can be used in animal models of disease.
Center for Aging, Genetics, and Neurodegeneration (CAGN) Laboratory for High-Throughput Screening
The CAGN of Massachusetts General Hospital is dedicated to the study of the 4 major neurodegenerative disorders: AD, PD, HD, and ALS. CAGN currently has 17 principal investigators with a breadth of specialties including genetics, biochemistry, molecular and cellular biology, and animal models of disease. Importantly, basic scientific studies at CAGN receive constant feedback from the clinical side because many of the investigators are clinical specialists in NDs.
A major effort of CAGN is to reduce the time from scientific discovery to development of new therapies. To facilitate this, an HTS laboratory was established in early 2002 to work exclusively with CAGN scientists. The goal of the lab is to assist investigators to adapt biochemical or cell-based assays for HTS and then to go on and screen these assays against the laboratory's collection of small molecules. With its limited focus, this laboratory is able to work closely with and meet the needs of the CGAN community of neuroscientists.
Cancer Drug Assays Initiative of the Dana-Farber/Harvard Cancer Center (DF/HCC)
The DF/HCC (http://www.dfhcc. The new laboratory at LDDN will be staffed by scientists with industrial experience in assay development and HTS and will work closely with investigators who bring innovative projects to the lab. These assays are now in the process of being identified, and collaborations are being established with the DF/HCC community of cancer scientists.
ESTABLISHING A SUCCESSFUL HTS LABORATORY IN ACADEMIA
To successfully establish, operate, and sustain an academic HTS laboratory, several concerns that are unique to this new enterprise must be attended to. Some of these are briefly described below.
Statement of mission
Perhaps the most important concern facing an academic institution wanting to establish an HTS lab is to clearly and unambiguously articulate this lab's mission. In formulating a mission statement, several key questions must be carefully considered and answered:
• Why is the lab being created? Is the lab being created to advance drug discovery or to engage in chemical genetics or to train students?
• How will this lab fulfill all aspects that its purpose comprises? For example, if the lab is being created for drug discovery, how will it move its programs from screening to animal efficacy studies? Are enabling resources available within the institution to bring molecules all the way to clinic? How will the screening lab position itself to mobilize these resources? If these resources are not available within the institution, will the institution be able to access personnel with the business development skills to creatively partner with pharma?
• What is the lab's role within the wider community of the institution? Who are its "clients"? How is the laboratory perceived-as an asset to the institution or as an out-of-place anomaly?
Without clear answers to these questions and a statement of mission, it will be impossible to formulate a strategy for how the lab will operate and how it will respond to other concerns and challenges facing it (see below).
Integration and enrichment of institutional culture
HTS is still a relatively new activity in academia and might be seen as something that is out of place here, being suitable only for industrial environments. There is, of course, some truth to this; it seems almost axiomatic that our institutions of higher learning should be engaged in the pursuit of hypothesis-driven discovery, not in mindless "fishing trips." Given this, one must be able, as mentioned above, to clearly state how the HTS that is being purposed will truly advance scientific understanding or how it will bring us closer to disease therapies. In this way, the culture of the parent institution will be enriched, and not diminished, by these new laboratories.
Funding: sustaining the mission
Opportunities for funding are clearly related to mission. Although chemical genetics and training might be supported by grants from government agencies, drug discovery can often obtain funding from disease-related foundations and pharmaceutical companies. But it is a truism that funds will always be tighter than we would like. Thus, it is important that these labs determine what elements of infrastructure (e.g., equipment, compound libraries, permanent staff, etc.) are truly necessary for the lab to accomplish its mission. If funds are not available for the essentials of the lab's mission, hard decisions will have to be made.
Intellectual property
If HTS hits or their chemically optimized offspring are ever to become the basis for the develop of therapeutics, it is critically important that matters relating to intellectual property be dealt with comprehensively and with forward thinking. An HTS laboratory that wishes to engage in drug discovery must devise an IP strategy that makes sense to pharma. At the very least, this means that 1) discoveries of the lab be protected prior to public disclosure, 2) assays and compounds be unencumbered by prior art (especially from other institutions and companies), and 3) the parent institution have appropriate business development, technology transfer, and patent staff to work competently with pharma.
FINAL THOUGHTS
The role and value of HTS in academic biological science has yet to be fully determined. Unfortunately, some investigators will see these methodologies as an excuse to forgo the hard intellectual work required of science and use HTS in the mindless pursuit of empty research programs. But for others, HTS will provide the tools to test previously untestable hypotheses and will thereby allow the discovery of the unanticipated and the truly novel.
